BioCentury
ARTICLE | Company News

FDA reviewing Shire’s constipation treatment

March 5, 2018 5:30 PM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA accepted for review its NDA for prucalopride (SHP555) to treat chronic idiopathic constipation (CIC) in adults. Its PDUFA date is Dec. 21.

Shire markets prucalopride, an agonist of serotonin (5-HT4) receptor, in the EU as Resolor. The company obtained the drug’s U.S. rights from Johnson & Johnson (NYSE:JNJ) in 2012...

BCIQ Company Profiles

Shire plc

BCIQ Target Profiles

Serotonin (5-HT4) receptor